Jan Hoflack, PhD

Jan Hoflack is a pharmaceutical scientist and drug discovery leader with over 30 years of experience spanning medicinal chemistry, structure-based drug design, kinase biology, and translational research. His work has focused on the discovery and development of first-in-class and best-in-class kinase inhibitors, with particular emphasis on macrocyclic chemotypes, target selectivity, and translational efficiency.

He has led multidisciplinary teams in large pharmaceutical organizations and co-founded biotechnology companies translating innovative chemistry platforms into clinical assets. 
He introduced the Nanocyclix® macrocyclic kinase inhibitor platform, which has generated multiple clinical-stage compounds, including programs targeting LRRK2 and RIPK2.

This technology has resulted in major industry partnerships and licensing agreements.

His expertise includes drug discovery strategy, platform innovation, AI integration in pharmaceutical research, academic–industry collaboration, and translation from target validation to clinical proof-of-concept. He is well positioned to contribute to research programs focused on mechanism-driven therapeutics, precision medicine, and innovative drug discovery paradigms.